Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQJAZZ),NASDAQ:EXELNASDAQEXEL)(NASDAQ:AMGNNASDAQAMGN,(NASDAQ:REGNNASDAQ) EQNX::TICKER_END

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer Moonshot” initiative. This ambitious plan, aimed […]

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (“ODD”) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQGNPX) ( Profile ) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (“SCLC”). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.’s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC NASDAQ: JAZZNASDAQJAZZ)(NASDAQ: ALXONASDAQALXO and Achilles Therapeutics PLC (NASDAQ: ACHLNASDAQ) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

EQNX::TICKER_START (NASDAQGNPX),(OTCQX:RHHBY),NASDAQ:JAZZNASDAQJAZZ)(NASDAQ:ALXONASDAQALXO,(NASDAQ:ACHLNASDAQ) EQNX::TICKER_END

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:JAZZNASDAQJAZZ)(NASDAQ:GERNNASDAQGERN,(NASDAQ:INABNASDAQ),(NASDAQ:VCYTVCYT) EQNX::TICKER_END

EQNX::TICKER_START (OTCQX:TCNNF),(OTCQX:CURLF),(NASDAQTLRY),NASDAQ:JAZZNASDAQJAZZ)

Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.

NetworkNewsWire Editorial Coverage : In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or chronic disease. It is particularly appropriate with a silent killer such as hypertension, a condition that all too often goes untreated, becoming a culprit in morbidity and mortality from cardiovascular, kidney and other serious diseases. Hypertension, or high blood pressure, stats continue to trend the wrong way, showing hundreds of thousands of people dying each year while costs of the disease are a major burden on already strained healthcare systems globally. Truth be told, hypertension is generally treatable with lifestyle changes and any number of prescription drugs, but most of the 1.28 billion people worldwide with high blood pressure go untreated. Because high blood pressure symptoms can be benign, patients would often rather go untreated than deal with unpleasant side effects of today’s drugs. A new, safer option made available through Lexaria Bioscience Corp. (NASDAQLEXX) ( Profile ) may offer blockbuster potential. Lexaria, a global innovator in drug-delivery platforms, is working its way through the FDA pathway. Lexaria completed the pre-investigational new drug (“IND”) application meeting process for its newest DehydraTECH(TM) delivery system with the U.S. Food and Drug Administration (“FDA”) and is proceeding with plans to file an IND as soon as possible and begin clinical studies shortly thereafter. Quietly going about its business, Lexaria maintains a low market capitalization compared to bigger peers, such as Jazz Pharmaceuticals plc NASDAQ: JAZZNASDAQJAZZ)(NYSE: JNJNYSEJNJ , United Therapeutics Corporation (NASDAQ: UTHRNASDAQ) and Bristol-Myers Squibb (NYSE: BMYBMY) , a fact the company…

NetworkNewsWire Editorial Coverage   New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or […]

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s, among others. According to Public Health England, the number of individuals with multiple sclerosis has increased over the last few years. This increase […]

2021 was a year to be easily forgotten for biotech stocks. The S&P 500 climbed 26.9%. However, SPDR S&P Biotech exchange-traded fund dropped 20.5%. Looks like 2022 will be “THE” year for biotech sector. In a recent note from Piper Sandler analyst Christopher Raymond and his colleagues, Raymond said that he recommended “selective buying” of biopharma stocks. On his list of top picks for the year are AbbVie (NYSEABBV), Horizon Therapeutics NASDAQ:HZNPNASDAQHZNP)(NYSE:BHVNNYSEBHVN, and Jazz Pharmaceuticals (NASDAQ:JAZZNASDAQ), among others.

New York, NY – August 5, 2021 – A leading cause of death in the United States for men and women of most racial and ethnic groups, heart disease is a pervasive health challenge that destroys lives. The Centers for Disease Control and Prevention (CDC) reports that one person dies every 36 seconds from cardiovascular disease. Treating the disease, as well as the conditions related to it such as high blood pressure, or hypertension, is a top priority for those in the medical space, and innovative companies are looking for ways to provide even more effective treatments. A leader in hypertension innovation, Lexaria Bioscience Corp. (NASDAQLEXX) ( Profile ) is focused on using its patented DehydraTECH(TM) drug delivery to identify safe and affordable treatments to the approximately 108 million, or almost one-half, of American adults dealing with high blood pressure. Innovation is a key characteristic of any successful company working in the pharma space, and other companies that are recognized as innovation leaders include Jazz Pharmaceuticals plc NASDAQ: JAZZNASDAQJAZZ)(NYSE: JNJNYSEJNJ, United Therapeutics Corporation (NASDAQ: UTHRNASDAQ) and Abbott Laboratorie s (NYSE: ABTABT).

Under the radar investment opportunities aren't necessarily rare but rather are hard to find. And one unpolished gem could be Agentix Corp. (OTC: AGTX), a company we estimate to have between 200,000 and 1,500,000 shares in its public float and is nearing, at least we believe, commercialization of a comprehensive suite of health solutions for patients and consumers. In fact, an 8K filed last Friday makes the stock more exciting and shows that AGTX is indeed on the move.

Palm Beach, FL – June 8, 2021 – The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe… and even the seemingly ever increasing Cannabidiol markets. The global COVID-19 pandemic outbreak has had an unprecedented and staggering impact on the global economy. This has negatively affected the demand for cannabidiol across all regions amid the pandemic. The global market exhibited a lower growth of 26.42% in 2020 compared to the average year-on-year growth during 2017-2019, however the market is projected to get back on the fast track grow from USD 3,675.1 million in 2021 at a CAGR of 47.49% between 2021 and 2028. The substantial rise in CAGR is attributed to the market’s demand and growth, coupled with the market functioning returning to pre-pandemic levels once the pandemic is over.  Industry reports, see higher acceptance from consumers, increasing government approvals and R&D on uses of medicinal cannabis will spur the markets higher for years to come.  A report from Fortune Business Insights said that: “Consumers seek innovative and healthy food products enriched with nutrients for achieving fitness goals and avoid injuries such as inflammation, pain, and others. The manufacturers are introducing products infused with novel ingredients such as CBD oil. Cannabidiol oils are the legalized and non-psychoactive element of cannabis that has conquered several industries such as food, health products, pharma & beauty, and others. According to the Harvard Health Institute 2018, CBD is commonly utilized to address human life’s health issues such as insomnia, anxiety, etc. Thus, the demand for such innovative CBD products from the consumer end proliferates to maintain a healthy life balance.”   Active Companies active today in the cannabis related markets include:  Jazz Pharmaceuticals (NASDAQJAZZ), Rapid Therapeutic Science Laboratories, Inc. (OTCPK: RTSL), Intec Pharma Ltd. NASDAQ: NTECNASDAQNTEC)(NASDAQ: CARANASDAQCARA, Arena Pharmaceuticals, Inc. (NASDAQ: ARNANASDAQ).

FN Media Group Presents Financialmorningpost.com Market Commentary

PAO Group, Inc. (USOTC: PAOG) stock closed 21% higher Monday preceding its planned investor update released this morning. In a pre-market release on Tuesday, PAOG updated investors about its expanding CBD-based therapeutics and nutraceuticals program that now includes two promising treatment candidates. The first is RespRx, targeting COPD, and the second, CBD RELAX-RX, a nutraceutical designed to treat anxiety and depression. The market opportunity is substantial, with estimates calling for at least a $25 billion combined market opportunity within five years.